Surprisingly, it may be tax reform — not Affordable Care Act repeal and replace — that has the greatest impact on the health care industry in 2017.
There was a time when lawmakers of opposing parties not only worked together, but also got along. They shared meals and got to know family members. And this was good for business.
Despite affecting as many 7 million people, cost-sharing reduction subsidies are often-ignored components of the Affordable Care Act.
With the health care industry in a state of limbo amid news of ACA repeal, repair and replace, one idea that has received far less attention than others is the concept of state flexibility.
As the repeal and replacement of the Affordable Care Act winds its way through Congress, one of the more popular parlor games in Washington these days is guessing what a post-ACA world will look like.
The pharmaceutical industry breathed a sigh of relief when Donald Trump was declared the next president of the United States. While not a wholly known entity, the devil the industry knew was a lot scarier than the devil it didn’t know. Hillary Clinton had spelled danger.
In the face of rising premiums and carrier exodus from markets across the country, leading Democrats and presidential candidate Hillary Clinton have expressed support for a public plan option for health insurance. Supporters say that a government-run plan would provide stability to the fragile – many would say “failing” – state health insurance exchanges.
The 21st Century Cures Act is an amalgam of ideas with one objective: improving the laborious process of moving medical innovation from the lab to patients’ bedsides. Two years in the making, this bipartisan effort — like any other in Washington — has been amended by compromise and political expedience.
There’s no question many cancer drugs and specialty pharmaceuticals are expensive, and their benefits often vary from patient to patient. Several years ago, a number of non-government organizations (NGOs) began launching “value frameworks” to help patients and payers decipher which drugs and devices may be most beneficial – and to provide guidance on appropriate […]
Information never stops. We help you start your day by making sense of it all. Over 150,000 government and industry executives rely on Morning Consult to stay informed. Our original reporting and morning email briefings make it possible for you to know everything you need to know, every day, at the intersection of Wall Street and business strategy, policy and politics.